Welcome to our dedicated page for DELCATH SYSTEMS SEC filings (Ticker: DCTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DELCATH SYSTEMS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DELCATH SYSTEMS's regulatory disclosures and financial reporting.
Delcath Systems, Inc. updated its corporate governance documents by amending and restating its Bylaws, effective August 12, 2026. The Board of Directors, following a recommendation from the Nominating and Corporate Governance Committee, adopted provisions specifying where certain legal disputes must be brought.
The revised Bylaws provide that, unless Delcath consents in writing to an alternative forum, the Court of Chancery of the State of Delaware (or, if it lacks subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for internal corporate claims. They also state that the federal district courts of the United States are the exclusive forum for claims arising under the Securities Act of 1933. The full Bylaws are filed as Exhibit 3.1.
Delcath Systems, Inc. reported continued profitability for the quarter ended June 30, 2026, driven by growing adoption of its liver cancer therapies. Quarterly revenue was $29,133 (in thousands), up from $24,156 (in thousands) a year earlier, with HEPZATO KIT contributing $27,161 (in thousands) and CHEMOSAT $1,972 (in thousands). Gross profit reached $26,148 (in thousands), and net income was $2,668 (in thousands), or $0.07 per diluted share.
Research and development expenses rose to $10,380 (in thousands) in the quarter and $20,204 (in thousands) year-to-date as the company advances Phase 2 trials in liver‑dominant metastatic colorectal and breast cancer. Selling, general and administrative expenses also increased with U.S. commercial expansion. Delcath ended June 30, 2026 with $47,521 (in thousands) in cash and cash equivalents and $48,381 (in thousands) in short‑term investments and states that these resources, plus operating cash flows, are expected to fund operations for at least 12 months. The company has repurchased 945,665 shares for about $9.0 million under a $25.0 million authorization, leaving roughly $16.0 million available.
Delcath Systems, Inc. reported second quarter 2026 results, with total revenue of $29.1 million, up from $24.2 million a year earlier, driven by HEPZATO KIT revenue of $27.1 million and CHEMOSAT revenue of $2.0 million. Gross margin rose to 90% from 86%, while net income was $2.7 million in both periods.
Non-GAAP adjusted EBITDA was $7.6 million, compared with $9.8 million in the prior-year quarter, and operating cash flow was $5.7 million. Cash and investments totaled $95.9 million as of June 30, 2026, with no debt, supporting expansion to 31 active treatment centers and ongoing clinical trials.
For full-year 2026, Delcath increased its revenue guidance for HEPZATO KIT and CHEMOSAT to $104–$108 million, targeting gross margins of 86–89% and positive adjusted EBITDA, and highlighted approximately 30% growth in HEPZATO volume and new data and trials across uveal melanoma and metastatic breast cancer.
BlackRock, Inc. has filed as a significant holder of Delcath Systems common stock. The firm reports beneficial ownership of 1,836,121 shares of common stock, representing 5.3% of the outstanding class.
BlackRock reports sole voting power over 1,807,103 shares and sole dispositive power over 1,836,121 shares, with no shared voting or dispositive power. The filing notes that various underlying clients and funds have rights to dividends or sale proceeds, but no single such person has an interest exceeding five percent of Delcath’s total outstanding common shares.
DELCATH SYSTEMS, INC. director John Richard Sylvester received a grant of stock options for 22,500 shares of common stock at an exercise price of $11.61 per share. The options vest in equal monthly installments, with one-twelfth vesting each month starting on May 13, 2026, as long as he remains a director. Any vested options expire the earlier of 10 years from the grant date or two years after his last day of service.
DELCATH SYSTEMS, INC. director Bridget A. Martell received a grant of stock options as equity compensation. The award covers 22,500 options for common stock at an exercise price of $11.61 per share, and she now holds 22,500 options following this grant.
These options vest in equal monthly installments of one-twelfth, starting on May 13, 2026, as long as she continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire on the earlier of 10 years from grant or two years after her service ends for vested portions.
DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and are compensation rather than an open-market purchase.
The award vests at a rate of one-twelfth per month, with the first vesting on May 13, 2026 and monthly thereafter while she remains a director under the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from the grant date or two years after her service ends.
DELCATH SYSTEMS, INC. director Steven A. J. Salamon received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and represent a compensation-related award, not an open-market purchase.
The options vest in equal monthly installments of one-twelfth of the grant, starting on May 13, 2026, as long as he continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire 10 years from the grant date or, for vested portions, two years after his last day of service.
DELCATH SYSTEMS, INC. director Aharon Gil received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and were awarded as compensation, not through an open-market purchase or sale.
The grant vests in equal monthly installments of one-twelfth of the total, starting on May 13, 2026, so long as Gil remains a director and subject to the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from grant or two years after service ends.
Delcath Systems, Inc. reported the results of its 2026 annual meeting of stockholders, where investors approved increasing the 2020 Omnibus Equity Incentive Plan by 1,800,000 shares of common stock. The plan provides additional shares for future equity-based awards to employees, directors and other participants.
Stockholders also elected two Class II directors to serve until the 2029 annual meeting, ratified CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2026, and approved a non-binding advisory vote on executive compensation. Of 34,618,159 eligible common and convertible preferred shares, 23,346,271 shares, or about 67.44%, were represented at the meeting, indicating a solid voting turnout.